Ignite Creation Date:
2025-12-24 @ 5:19 PM
Ignite Modification Date:
2026-01-13 @ 12:52 PM
Study NCT ID:
NCT06253650
Status:
RECRUITING
Last Update Posted:
2024-06-13
First Post:
2024-02-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
Sponsor:
Gruppo Oncologico del Nord-Ovest
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
2023-506662-31-00
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None